SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes
This video was recorded at the ESC in Paris, France, on September 1, 2019.
John McMurray BSc (Hons) MB ChB (Hons) MD FRCP FESC FACC FAHA FRSE FMedSci is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow
This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: